Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)
SJR10 is a Nevada joint resolution urging Congress and federal agencies to take several actions related to the therapeutic use of psychedelic compounds. The resolution cites research and federal developments involving psilocybin, psilocin, DMT, ibogaine, mescaline, and MDMA, arguing that these substances show promise for treating PTSD, treatment-resistant depression, anxiety disorders, substance use disorders, chronic pain, and related conditions, especially for veterans and first responders. It also references FDA Breakthrough Therapy designations, clinical trial results, and federal research efforts as support for expanding access and study.
The resolution asks Congress and federal agencies to increase funding for psychedelic research, create a streamlined federal research approval process, and establish a compassionate-use pathway under the Right to Try Act for eligible investigational psychedelic drugs. It further urges rescheduling of the listed compounds to better reflect their medical potential and low abuse risk, and calls for legal protections for supervised adult use under state and local law. The measure is advisory rather than regulatory, so it does not directly change Nevada criminal law or controlled-substance scheduling; instead, it expresses the Legislature’s position and requests federal action while supporting expanded research at qualified Nevada institutions.
Because SJR10 is a joint resolution, it does not amend Nevada statutes or create state regulatory requirements. Its legal effect is limited to expressing the Legislature’s support for federal policy changes, including rescheduling psychedelic substances, expanding research access, and protecting supervised adult use under state and local law. The resolution also formally transmits Nevada’s position to federal officials and agencies, including Congress, DEA, and NIH, and signals support for psychedelic research at Nevada institutions.
The overall sentiment reflected in the resolution is strongly supportive of psychedelic-assisted therapy and research. The bill frames these compounds as promising tools for addressing unmet mental health and pain-treatment needs, particularly for veterans, and emphasizes growing federal and academic interest. No committee debate or recorded vote information was provided, so there is no documented opposition or amendment history in the supplied materials.
The main points of contention implied by the resolution are the federal Schedule I classification of psychedelic compounds, the barriers that classification creates for research, and whether these substances should be made available for compassionate use or supervised adult use. Supporters of the resolution argue that the scientific evidence and FDA designations justify rescheduling and expanded access, while the resolution’s language suggests that current federal law is too restrictive. Because no transcripts or votes were provided, no specific legislator or stakeholder opposition is identified in the record supplied.